Pregled bibliografske jedinice broj: 880979
Pharmacoeconomics: How It Can Be Applied To Support Decisions In Health Care?
Pharmacoeconomics: How It Can Be Applied To Support Decisions In Health Care? // Abstracts Presented at the European Association for Clinical Pharmacology and Therapeutics Focus Meeting 2016: How to Assess Medicines from Research to Clinical Practice? Efficacy, Effectiveness, and Economic– 3E Assessment / Richard I. Shader (ur.).
Amsterdam : Boston : Jena : London: Elsevier, 2016. str. e13-e13 (pozvano predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 880979 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pharmacoeconomics: How It Can Be Applied To Support Decisions In Health Care?
Autori
Vitezić, Dinko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts Presented at the European Association for Clinical Pharmacology and Therapeutics Focus Meeting 2016: How to Assess Medicines from Research to Clinical Practice? Efficacy, Effectiveness, and Economic– 3E Assessment
/ Richard I. Shader - Amsterdam : Boston : Jena : London : Elsevier, 2016, E13-e13
Skup
European Association for Clinical Pharmacology and Therapeutics Focus Meeting 2016
Mjesto i datum
Opatija, Hrvatska, 06.10.2016. - 09.10.2016
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Pharmacoeconomics ; Reimbursement ; Health Technology Assessment
Sažetak
The problem of the limited health care resources is worldwide present, and this logically leads to increased interest in assessing the value for money, or economic efficiency, of new medicines and therapies. The cornerstone in this process of assessment belongs to pharmacoeconomics, which is defined as a scientific discipline that analyses the values of one medicine or medical intervention to another. Pharmacoeconomic evaluation is relevant to decisions about the pricing and reimbursement of different procedures and health technologies, since it offers a way of estimating the additional value to society of a new intervention (e.g., medicine) in comparison to existing therapy. The most frequently used pharmacoeconomic analysis includes cost-effectiveness (CEA) and cost-utility analyses (CUA). These techniques are most appropriately applied when a choice must be made between two or more competing options for which the expected health gains can be expressed in terms of a common outcome measure. It is necessary to emphasize that pharmacoeconomic evaluation as a part of health technology assessment (HTA) is applicable to review therapeutic areas and especially with significant budget impact, including the revision of therapeutic guidelines and financing protocols and delisting of previously reimbursed pharmaceuticals. The importance of such an evidence-based health policy is widely acknowledged among health care policy-makers all over the world. Pharmacoeconomics as part of HTA is a transparent process that provides health care decision-makers with valuable information. This is used in a decision concerning the optimal health care resource allocation in a standardized and scientifically consistent process.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
062-0620063-0060 - Uporaba kardiovaskularnih lijekova i značaj farmakoekonomskih procjena (Vitezić, Dinko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Rijeka
Profili:
Dinko Vitezić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Scopus
- MEDLINE